A Double-Blind, Placebo-Controlled, Dose-Escalation, First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2017
At a glance
- Drugs IONIS-HBV-LRx (Primary)
- Indications Hepatitis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 25 Jan 2017 Status changed from active, no longer recruiting to completed.
- 12 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.